is a privately held clinical stage biotech company based in Darmstadt, Germany.
The Company focuses on disorders linked to the enzyme family of transglutaminases
Zedira’s business model
is focused on the development of small molecule drug candidates for early licensing.
Zedira’s drug candidate
for celiac disease therapy, tissue transglutaminase (TG2) blocker ZED1227
is currently tested in phase 2a clinical trials
is licensed to Dr. Falk Pharma for Europe and four other countries. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.
Current internal development work focuses on second generation TG2
inhibitors optimized for systemic indications. Zedira medicinal chemists discovered a novel class of reversible-acting
blockers combining high potency
along with excellent selectivity
. Zedira taps the potential of these oral bio available compounds to address systemic indications, especially fibrotic disorders (e.g. diabetic nephropathy).
Further, Zedira developed coagulation FXIIIa blockers
(F13a, plasma transglutaminase) for safe anticoagulation (thromboprophylaxis)
. This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs.
In a rabbit animal model, Zedira
already showed the proof of principle of “safe” anticoagulation therapy by inhibition of Factor XIIIa
The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.Zedira
’s managing partners, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal: